Leucopenia after gold and sulphasalazine treatment.

HLA types in patients with rheumatoid arthritis developing leucopenia after both gold and sulphasalazine treatment.

HLA types, especially HLA-DR3, are associated with the development of toxic reactions in patients with rheumatoid arthritis after treatment with gold or D-penicillamine. In this study, after treatment with sulphasalazine, leucopenia was observed in three patients, who all had a history of leucopenia after previous gold treatment. The HLA types of these patients did not include HLA-DR3; the two ...

Leucopenia during sulphasalazine treatment for rheumatoid arthritis.

Leucopenia appears to be a more frequent complication of sulphasalazine treatment in rheumatoid arthritis than in inflammatory bowel disease and poses a management problem. In this study leucopenia was found in 20 patients, 14 of whom were participating in prospective studies (252 patients), giving an incidence of 5.6%. Treatment had to be discontinued in half of these patients. Most (14) episo...

Bone marrow necrosis after treatment with sulphasalazine.

Inhibition of xanthine oxidase by allopurinol: its lack of effect on models of inflammation.

and 'lupus like' disease: association with anti-phospholipid antibodies. Leucopenia after gold and sulphasalazine treatment Sir: I read the interesting report by Bliddal and colleagues of three patients who developed leucopenia after both gold and sulphasalazine treatment.' HLA-DR3 as a marker for toxic reactions after treatment with gold or D-penicillamine could not be shown. Patient 1, howeve...

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.

AIM We evaluated the effect of coadministration of sulphasalazine, mesalamine, and balsalazide on the pharmacokinetics and pharmacodynamics of azathioprine and 6-mercaptopurine. METHODS Thirty four patients with Crohn's disease receiving azathioprine or 6-mercaptopurine were enrolled in an eight week non-randomised parallel group drug interaction study and treated with mesalamine 4 g/day, sul...